Ice Cream, You Scream, We All Scream for Ice Cream!
Ahhhh… ice cream. A frosty treat that’s perfect on a hot summer day – or anytime, really! This delicious frozen delight is one of America’s number one dessert choices and like America, one of the most magnificent things about ice cream is its diversity. It is truly remarkable all the different varieties and flavors available today, and the opportunity that exists to create something that suits your unique tastes – the freedom of culinary expression, if you will. Continue reading
An Open Letter to President Elect Donald Trump
January 15, 2017
Dear President Elect Trump,
I hope you will thoughtfully respond to this public appeal, and that you will use your powers as the President of the United States to transform our country in meaningful ways, which fulfill your campaign promise to “Make America Great Again.”
Accordingly, I pray that you will honor the majority of the American people, and decisively act in a bold new direction by legalizing cannabis. I ask you to single-handedly choose to rewrite history regarding this unfairly demonized plant, and refuse to play politics as usual, and open the doors to Marijuana-based medicine for millions of American patients in need.
The following is no way an attempt to take a victory lap. It is a simple and common performance analysis of my work over the last 90 days. On July 20, I published “Advisory on Stocks in the Legal Marijuana Sector,” highlighting 4 different stocks in the Cannabis sector; GW Pharma (GWPH), Zynerba (ZYNE), Kush Bottles (KSHB), and Mass Roots (MSRT). For historical purposes, all price quotes are marked to the close of business on July 19, 2016 and closing prices for 90 day performance analysis are marked to the close of business October 17, 2016.
A Modern Day Tale of Lies and Corruption, and Our Nation’s Fall From Grace
By Alexander Nachman
Cannabis Advocate, Investment Advisor, and Concerned Citizen
Synthetic THC has been FDA approved since 1985 and is currently listed as a Schedule III drug. Currently over 20 U.S. Pharmaceutical firms are working on cannabis-based medicines that will mimic, reproduce, and create bio-identical cannabinoid molecules to be turned into pharmaceutical medicine.
The most ironic thing about this is that the DEA just ruled that Marijuana – the actual plant – will remain a Schedule I drug with “no medicinal value,” and is in the same category as drugs like Heroin and LSD. Continue reading
Alexander Nachman, America’s leading expert on investing in the cannabis industry, commented on the quality of several cannabis stocks and their potential upside and risk.
I am continually asked about the current state of the market, as well as what cannabis stocks I find value in and what near term catalysts might spur profits in the cannabis sector. Continue reading
Dear Mr. President,
In light of recent events, you have an opportunity, dare I say an obligation, to fundamentally change America in a profound manner. You can enact an Executive Order that can solve some of this country’s biggest problems, and right some of our most egregious wrongs. Continue reading
A survey of more than 216,000 adolescents from all 50 states indicates the number of teens with marijuana-related problems is declining. Similarly, the rates of marijuana use by young people are falling despite the fact more U.S. states are legalizing or decriminalizing marijuana use and the number of adults using the drug has increased.
Researchers at Washington University School of Medicine in St. Louis examined data on drug use collected from young people, ages 12 to 17, over a 12-year span. They found that the number of adolescents who had problems related to marijuana — such as becoming dependent on the drug or having trouble in school and in relationships — declined by 24 percent from 2002 to 2013.
Back in April, the U.S. Drug Enforcement Administration announced it would be reviewing the possibility of changing the federal classification of marijuana from Schedule 1 to Schedule 2.
Marijuana is currently listed among the DEA’s Schedule 1 drugs, which it describes as “most dangerous” and having “a high potential for abuse.” Other Schedule 1 drugs include heroin and LSD. Continue reading
The headquarters of Weedmaps, the most influential company in California’s medical-marijuana industry, is hidden inside a gray, two-story office building at the intersection of Irvine Center Drive and Discovery in Irvine. Inside the green-accented lobby, the first hint that you’ve just entered a 420-friendly business is a faint trace of marijuana odor.
Within a year of Weedmap’s founding in 2008, the company’s website was already bringing in $300,000 per month in advertising revenue—from storefront dispensaries, delivery services and doctor referral providers. By 2013, Weedmaps was generating $1.5 million per month. In 2014, the most recent year for which the company’s financial data is available, Weedmaps was earning at least $30 million from listings.